Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 10/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13681826 | 1.00 | NPC1 (0.47) | NPC1RAB9ACTSLCTSSCNR2 | |
| SCHEMBL131149 | 0.96 | BIRC2 (0.47) | NPC1RAB9ACNR2MMP2BIRC2 | |
| SCHEMBL130361 | 0.96 | BIRC2 (0.47) | NPC1RAB9ACNR2MMP2BIRC2 | |
| SCHEMBL13681831 | 0.85 | CTSL (0.41) | NPC1RAB9ACTSLCTSSCNR2 | |
| SCHEMBL13681824 | 0.85 | CTSL (0.41) | NPC1RAB9ACTSLCTSSCNR2 | |
| SCHEMBL16898303 | 0.85 | NPC1 (0.50) | NPC1RAB9ACNR2 | |
| SCHEMBL16898305 | 0.85 | NPC1 (0.50) | NPC1RAB9ACNR2 | |
| SCHEMBL4392476 | 0.83 | NPC1 (0.43) | NPC1RAB9ACA1CA2CA9 | |
| SCHEMBL4392472 | 0.83 | NPC1 (0.43) | NPC1RAB9ACA1CA2CA9 | |
| SCHEMBL3944730 | 0.82 | NPC1 (0.43) | NPC1RAB9ACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589216-B2 | Process for preparing N-hydroxyformamido-propyl pyrrolidin compounds and intermediates | NOVARTIS AG (CH) | 2009-09-15 | — | — | US | disclosed |
| US-7589216-B2 | Process for preparing N-hydroxyformamido-propyl pyrrolidin compounds and intermediates | NOVARTIS AG (CH) | 2009-09-15 | — | — | US | disclosed |
| US-7589216-B2 | Process for preparing N-hydroxyformamido-propyl pyrrolidin compounds and intermediates | NOVARTIS AG (CH) | 2009-09-15 | — | — | US | disclosed |
| EP-1542968-B1 | PROCESS FOR PREPARING INTERMEDIATES | NOVARTIS AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| EP-1542968-B1 | PROCESS FOR PREPARING INTERMEDIATES | NOVARTIS AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-20050261504-A1 | Process for preparing intermediates | NOVARTIS AG (CH) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261504-A1 | Process for preparing intermediates | DHPS, PDF, HPN | NPC1 3440/4885RAB9A 3733/4885CTSL 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.